Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Mol Cancer Ther (2022) 21 (4): 700.

https://doi.org/10.1158/1535-7163.MCT-22-0104

Published: 01 April 2022

View article titled, Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Journal Articles

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Mol Cancer Ther (2021) 20 (10): 1820–1835.

https://doi.org/10.1158/1535-7163.MCT-21-0013

Published: 01 October 2021

View article titled, Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Journal Articles

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors

John H. Strickler, Patricia LoRusso, Ravi Salgia, Yoon-Koo Kang, Chia Jui Yen, Chia-Chi Lin, Peter Ansell, Monica Motwani, Shekman Wong, Huibin Yue, Lan Wang, Edward Reilly, Daniel Afar, Louie Naumovski, Ramesh K. Ramanathan

Mol Cancer Ther (2020) 19 (5): 1210–1217.

https://doi.org/10.1158/1535-7163.MCT-19-0529

Published: 04 May 2020

View article titled, Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer

Nellie K McDaniel, Mari Iida, Kwangok P Nickel, Tamara S Rodems, Adam D Swick, Prashanth J Prabakaran, Jaimee C Eckers-Kubatzke, Noah B Welke, Carlene Kranjac, Alison E Schulz, Randy J Kimple, Ravi Salgia, Deric L Wheeler

Mol Cancer Ther (2019) 18 (12_Supplement): A128.

https://doi.org/10.1158/1535-7163.TARG-19-A128

Published: 01 December 2019

View article titled, Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer

Journal Articles

Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer

Toni M. Brand, Mari Iida, Emily F. Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David Yang, Kari B. Wisinski, Ravi Salgia, Deric L. Wheeler

Mol Cancer Ther (2019) 18 (4): 868.

https://doi.org/10.1158/1535-7163.MCT-18-1183

Published: 01 April 2019

View article titled, Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer

Journal Articles

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale

Ravi Salgia

Mol Cancer Ther (2017) 16 (4): 555–565.

https://doi.org/10.1158/1535-7163.MCT-16-0472

Published: 02 April 2017

View article titled, MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale

Journal Articles

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

Mari Iida, Harsh Bahrar, Toni M. Brand, Hannah E. Pearson, John P. Coan, Rachel A. Orbuch, Bailey G. Flanigan, Adam D. Swick, Prashanth J. Prabakaran, Johan Lantto, Ivan D. Horak, Michael Kragh, Ravi Salgia, Randy J. Kimple, Deric L. Wheeler

Mol Cancer Ther (2016) 15 (9): 2175–2186.

https://doi.org/10.1158/1535-7163.MCT-16-0012

Published: 01 September 2016

View article titled, Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

Journal Articles

A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors

Kari L. Kendra, Ruth Plummer, Ravi Salgia, Mary E. R. O'Brien, Elaine M. Paul, A. Benjamin Suttle, Natalie Compton, Chun-Fang Xu, Lone H. Ottesen, Miguel A. Villalona-Calero

Mol Cancer Ther (2015) 14 (2): 461–469.

https://doi.org/10.1158/1535-7163.MCT-14-0431

Published: 09 February 2015

View article titled, A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

Toni M. Brand, Mari Iida, Emily F. Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David Yang, Kari B. Wisinski, Ravi Salgia, Deric L. Wheeler

Mol Cancer Ther (2014) 13 (5): 1356–1368.

https://doi.org/10.1158/1535-7163.MCT-13-1021

Published: 05 May 2014

View article titled, Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer

Cleo E. Rolle, Rajani Kanteti, Mosmi Surati, Suvobroto Nandi, Immanuel Dhanasingh, Soheil Yala, Maria Tretiakova, Qudsia Arif, Todd Hembrough, Toni M. Brand, Deric L. Wheeler, Aliya N. Husain, Everett E. Vokes, Ajit Bharti, Ravi Salgia

Mol Cancer Ther (2014) 13 (3): 576–584.

https://doi.org/10.1158/1535-7163.MCT-13-0109

Published: 09 March 2014

View article titled, Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer

Journal Articles

Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers

Mohamed El Dinali, Johannes Braegelmann, Thomas Stricker, Christopher Brown, Ravi Salgia, Everett Vokes, Kevin White, Tanguy Seiwert

Mol Cancer Ther (2009) 8 (12_Supplement): A207.

https://doi.org/10.1158/1535-7163.TARG-09-A207

Published: 10 December 2009

View article titled, Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers

Journal Articles

Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines

Johanna Zoergiebel, Abir Kundu, Johannes Braegelmann, Wanda Shen, Mohamed El Dinali, Ravi Salgia, Tanguy Seiwert

Mol Cancer Ther (2009) 8 (12_Supplement): A165.

https://doi.org/10.1158/1535-7163.TARG-09-A165

Published: 10 December 2009

View article titled, Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines

Journal Articles

Abstract C78: The mu opioid receptor regulates Lewis lung carcinoma tumor growth and metastasis

Biji Mathew, Frances E. Lennon, Jessica Siegler, Lynnette Gerhold, Nurbek Mambetsariev, Liliana Moreno‐Vinasco, Joe G.N. Garcia, Ravi Salgia, Jonathan Moss, Patrick Singleton

Mol Cancer Ther (2009) 8 (12_Supplement): C78.

https://doi.org/10.1158/1535-7163.TARG-09-C78

Published: 10 December 2009

View article titled, Abstract C78: The mu opioid receptor regulates Lewis lung carcinoma tumor growth and metastasis

Journal Articles

Abstract C79: Methylnaltrexone inhibits EGF‐ and IGF‐induced human bronchioloalveolar carcinoma proliferation and migration

Frances E. Lennon, Nurbek Mambetsariev, Joe G.N. Garcia, Ravi Salgia, Jonathan Moss, Patrick A. Singleton

Mol Cancer Ther (2009) 8 (12_Supplement): C79.

https://doi.org/10.1158/1535-7163.TARG-09-C79

Published: 10 December 2009

View article titled, Abstract C79: Methylnaltrexone inhibits EGF‐ and IGF‐induced human bronchioloalveolar carcinoma proliferation and migration

Journal Articles

A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies

Ravi Salgia, David Hong, Steven Sherman, Chann Ng, John Frye, Linda Janish, Mark Ratain, Razelle Kurzrock

Mol Cancer Ther (2007) 6 (11_Supplement): A152.

Published: 01 November 2007

View article titled, A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies

NARROW

Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors

Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer

Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors

Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer

Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers

Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines

Abstract C78: The mu opioid receptor regulates Lewis lung carcinoma tumor growth and metastasis

Abstract C79: Methylnaltrexone inhibits EGF‐ and IGF‐induced human bronchioloalveolar carcinoma proliferation and migration

A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only